Literature DB >> 9788829

Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.

N M Lakkis1, S F Nagueh, N S Kleiman, D Killip, Z X He, M S Verani, R Roberts, W H Spencer.   

Abstract

BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is frequently responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM). Medical therapy is often not sufficient to control these symptoms, and surgical myotomy-myomectomy is required. METHODS AND
RESULTS: We enrolled 33 symptomatic patients with HOCM and obstruction (>/=40 mm Hg gradient at rest or >/=60 mm Hg dobutamine-provoked). By contrast echocardiography, the bulging septum was localized and infarcted by injection of 2 to 5 mL of absolute ethanol into the septal artery(ies) supplying the hypertrophied area. Baseline echocardiograms with Doppler, myocardial perfusion tomograms, and treadmill exercise or pharmacological testing were compared with those at 6 weeks and 6 months. The mean rise in creatine kinase was 1964+/-796 U. All patients experienced symptomatic relief; NYHA class decreased from 3. 0+/-0.5 to 0.9+/-0.6 (P<0.001). Exercise time increased from 286+/-193 to 421+/-181 seconds (P=0.03). The resting and dobutamine-provoked gradient decreased from 49+/-33 and 96+/-34 mm Hg to 9+/-19 (P<0.001) and 24+/-31 mm Hg (P<0.001), respectively. Echocardiograms repeated at 6 weeks after the procedure showed a 28% reduction in septal thickness and 17% reduction in left ventricular mass. Myocardial perfusion imaging showed a "septal amputation pattern," with scarring in the upper and middle septal areas. Complete heart block developed in 11 patients, who then required permanent pacemaker implantation.
CONCLUSIONS: Echocardiography-guided ethanol septal reduction in patients with HOCM is a safe, minimally invasive procedure that provides symptomatic relief with improved hemodynamic and left ventricular parameters.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788829     DOI: 10.1161/01.cir.98.17.1750

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Complete heart block complicating alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  T O Cheng
Journal:  Tex Heart Inst J       Date:  1999

Review 2.  Emerging indications for permanent pacing.

Authors:  D L Wolbrette; G V Naccarelli
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

3.  Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Authors:  Felix Y j Keng; Su Min Chang; Eduardo Cwajg; Zuo-Xiang He; Nasser M Lakkis; Sherif F Nagueh; William H Spencer; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

4.  A new technique for the transvenous implantation of the over-the-wire left ventricular pacing lead in a patient with heart failure.

Authors:  Cheuk-Man Yu; Raymond Miu
Journal:  J Interv Card Electrophysiol       Date:  2002-10       Impact factor: 1.900

Review 5.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

6.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

7.  A case of ventricular asystole without escape rhythm 4 days after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy with drug-resistant paroxysmal atrial fibrillation.

Authors:  Mitsunori Ohtsubo; Hiroto Sakai; Hisashi Kon; Hideyuki Takano
Journal:  J Cardiol Cases       Date:  2011-08-11

8.  Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy.

Authors:  C van der Lee; D P Foley; W B Vletter; F J Ten Cate; M J M Kofflard
Journal:  Neth Heart J       Date:  2001-05       Impact factor: 2.380

9.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

10.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Authors:  Debby Ngo; Sumita Sinha; Dongxiao Shen; Eric W Kuhn; Michelle J Keyes; Xu Shi; Mark D Benson; John F O'Sullivan; Hasmik Keshishian; Laurie A Farrell; Michael A Fifer; Ramachandran S Vasan; Marc S Sabatine; Martin G Larson; Steven A Carr; Thomas J Wang; Robert E Gerszten
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.